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Pyrrole-imidazole polyamide (PIP) is a nuclease-re-
sistant novel compound that inhibits gene expression
through binding to the minor groove of DNA. Human
aurora kinase-A (AURKA) and -B (AURKB) are impor-
tant regulators in mitosis during the cell cycle. In this
study, two specific PIPs (PIP-A and PIP-B) targeting
AURKA andAURKBpromoter regionswere designed
and synthesized, and their biological effects were in-
vestigatedby several in vitro assays. PIP-AandPIP-B
significantly inhibited the promoter activities, mRNA
expression, andprotein levels of AURKAandAURKB,
respectively, in a concentration-dependent manner.
Moreover, 1:1 combination treatment with both PIPs
demonstrated prominent antiproliferative synergy
(CI value [ED50] = 0.256) to HeLa cells as a result of
inducing apoptosis-mediated severe catastrophe of
cell-cycle progression. The novel synthesized PIP-A
and PIP-B are potent and specific gene-silencing
agents for AURKA and AURKB.
INTRODUCTION
Small molecules that preferentially bind to predetermined DNA
sequences inside living cells would be useful tools in molecular
biology and, perhaps, in human medicine (Bando et al., 2002;
Best et al., 2003; Bischoff et al., 1998; Carvajal et al., 2006;
Chou and Talalay, 1984). The effectiveness of these small mole-
cules requires not only that they bind to chromosomal DNA
in a site-specific manner, but also that they are permeable to
the outer membrane and gain access to the nuclei of living cells
(Best et al., 2003; Dervan, 2001; Nickols and Dervan, 2007;
Nickols et al., 2007; Trauger et al., 1996).
Pyrrole-imidazole polyamide (PIP) was first identified from du-
carmycin A and distamycin A by Dervan, et al. (Best et al., 2003;Chemistry & Biology 15, 8Dervan, 2001; Nickols and Dervan, 2007; Nickols et al., 2007;
Trauger et al., 1996). PIPs are small synthetic molecules com-
posed of the aromatic amino acids N-methylpyrrole (Py) and
N-methylimidazole (Im) (Bando et al., 2002; Best et al., 2003;
Dervan, 2001; Matsuda et al., 2006; Murty and Sugiyama,
2004; Nickols and Dervan, 2007; Nickols et al., 2007; Trauger
et al., 1996; Zhang et al., 2006). Synthetic PIPs recognize and
bind to specific nucleotide sequences in the minor groove of
double-helical DNA with high affinity and block the binding of
specific proteins (Bando et al., 2002; Best et al., 2003; Dervan,
2001; Matsuda et al., 2006; Murty and Sugiyama, 2004; Nickols
and Dervan, 2007; Nickols et al., 2007; Trauger et al., 1996;
Zhang et al., 2006). There is a set of pairing rules for the interac-
tion between these heterocyclic rings (Py and Im) and nucleotide
base pairs in the minor groove; pairing of Im opposite Py (Im/Py)
specifically binds to the G-C base pair, Py/Im is specific for the
C-G base pair, and Py/Py binds to both the A-T and T-A base
pairs (Bando et al., 2002; Best et al., 2003; Dervan, 2001;
Matsuda et al., 2006; Murty and Sugiyama, 2004; Nickols and
Dervan, 2007; Nickols et al., 2007; Trauger et al., 1996; Zhang
et al., 2006). In addition, synthetic PIPs are resistant to nucleases
and do not require particular delivery systems, unlike such con-
ventional gene silencing agents as antisense DNA, ribozymes,
and siRNA (Bando et al., 2002; Best et al., 2003; Dervan, 2001;
Matsuda et al., 2006; Murty and Sugiyama, 2004; Nickols and
Dervan, 2007; Nickols et al., 2007; Trauger et al., 1996; Zhang
et al., 2006). Therefore, PIPs may be useful tools in molecular
biology medicine.
Members of the Aurora/Ipl1p kinase family, which are among
the serine/threonine kinases, are highly conserved in diverse
eukaryotes and are thought to play important roles in normal
chromosome segregation and cytokinesis (Carvajal et al.,
2006; Kimura et al., 2004; Tanaka et al., 2002). Three types of
human Aurora/Ipl1p family protein kinases—Aurora kinase-A
(AURKA), Aurora kinase-B (AURKB), and Aurora kinase-C
(AURKC) —have been identified in different aspects of mitosis
(Carvajal et al., 2006; Kimura et al., 2004; Tanaka et al., 2002).
AURKA localizes to centrosomes and is required for centrosome29–841, August 25, 2008 ª2008 Elsevier Ltd All rights reserved 829
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(Carvajal et al., 2006; Tanaka et al., 2002). AURKB demonstrates
a typical localization pattern of chromosomal passenger proteins
that relocate from the centromeres to the equatorial region along
themidzone after the onset of anaphase (Carvajal et al., 2006; Ki-
mura et al., 2004). AURKB is an essential factor for chromosome
alignment, kinetochore-microtubule attachment, chromosome
segregation, and cytokinesis (Carvajal et al., 2006; Kimura
et al., 2004). AURKC is specifically and abundantly expressed
in the testis, where it functions in spermatogenesis and regula-
tion of cilia and flagella. However, its role in cancer development
is currently unclear (Carvajal et al., 2006). AURKA and AURKB
mRNA expressions are regulated in a cell-cycle-dependent
manner (Carvajal et al., 2006; Kimura et al., 2004; Tanaka
et al., 2002). The levels of mRNA, protein, and kinase activity in
both AURKA and AURKB are low during the G1/S phase, accu-
mulate during the G2/M phase, and decrease rapidly after mito-
sis (Carvajal et al., 2006; Kimura et al., 2004; Tanaka et al., 2002).
Their ectopic overexpression in cultured cells leads to centro-
some abnormality and chromosome aneuploidy, and then
results in either cell death or survival through malignant transfor-
mation (Bischoff et al., 1998; Carvajal et al., 2006; Jung et al.,
2006; Kanda et al., 2005; Kimura et al., 2004; Meraldi et al., 2002;
Ota et al., 2002; Sorrentino et al., 2005; Tanaka et al., 2002). In
addition, the high-level expression of AURKA or AURKB is
exhibited in various human cancer cells and tumor cell lines
(Bischoff et al., 1998; Carvajal et al., 2006; Jung et al., 2006;
Kanda et al., 2005; Kimura et al., 2004; Meraldi et al., 2002;
Ota et al., 2002; Sorrentino et al., 2005; Tanaka et al., 2002).
To develop novel anticancer agents, the authors designed and
synthesized two specific PIPs targeting AURKA and AURKB
promoter regions. These synthetic PIPs—PIP-A and PIP-B for
AURKA and AURKB promoter, respectively—were investigated,
and their biological effects in cellular systems were evaluated by
use of in vitro assays.
RESULTS
Structure of Novel PIPs Targeting AURKA and AURKB
Promoter
The gene encoding AURKA is located on chromosome 20q13.2
(Carvajal et al., 2006; Tanaka et al., 2002), and the sequence is
available from the DDBJ/EMBL/GenBank data base (acces-
sion number AL121914). The PIP targeting AURKA (PIP-A) was
designed to span the boundary of the previously reported posi-
tive regulatory element (PRE) (85 to 79) on the AURKA pro-
moter, and it recognized 7 bp (Figure 1Aa; Tanaka et al., 2002).Chemistry & Biology 15, 8The gene encoding AURKB is located on chromosome
17p13.1 (accession number AC135178) (Carvajal et al., 2006;
Kimura et al., 2004). The PIP targeting AURKB (PIP-B) was de-
signed to span the boundary of the previously reported cell-cycle
gene homology region (CHR) (21 to 17) on the AURKB pro-
moter, and it recognized 8 bp (Figure 1Ab; Kimura et al., 2004).
The numberings refer to the previously reported major transcrip-
tional initiation site as +1 (Figure 1A; Kimura et al., 2004; Tanaka
et al., 2002). PRE and CHRwere previously described as playing
important roles in the cell-cycle-dependent regulation of AURKA
or AURKB gene expression (Kimura et al., 2004; Tanaka et al.,
2002).
The structures of both novel synthesized PIPs (PIP-A and
PIP-B) are shown in Figure 1A. The physical and chemical char-
acterizations of both PIPs, as analyzed by electrospray ionization
mass spectrometry (ESI-Mass) and HPLC, are shown in Fig-
ure S1 available online. The PIPs were dissolved in DMSO at
10 mM, were stored at room temperature, and then were freshly
diluted to appropriate concentrations in pure water or growth
medium.
DNA-Binding Assay Results
Electromobility shift assay (EMSA) and Biacore assays allow for
determination of the binding affinity and specificity of PIP-A and
PIP-B for target nucleotide sequences. In EMSA, PIP-A bound to
the appropriate 22 bp AURKA ‘‘match’’ double strand (ds)-oligo-
nucleotides (oligo) (Table S1). The clear mobility band that indi-
cates specific binding of PIP-A and match ds-oligo was demon-
strated in Figure 1Ba, lane 4, whereas PIP-A did not bind to the 2
bp mutated ‘‘mismatch-1’’ ds-oligo and ‘‘mismatch-2’’ alternate
AURKB ds-oligo (Table S1). No mobility band was detected for
both mismatch ds-oligos (Figure 1Ba, lanes 5 and 6). Similarly,
PIP-B also bound to the appropriate 22 bp AURKB match
ds-oligo but did not bind to both mismatch-1 and mismatch-2
ds-oligos (Table S1; Figure 1Bb, lanes 4, 5, and 6).
The kinetics of interaction between PIP and match or mis-
match ds-oligo was measured by Biacore assay (Table S1). In
surface plasmon resonance sensorgrams, fast and strong bind-
ings of PIP-A and PIP-B to the appropriate AURKA and AURKB
match ds-oligo were demonstrated, and these match bindings
reached equilibrium at high PIP concentrations (Figure 1Ca),
whereas the bindings between both PIPs and the 2 bp mutated
mismatch-1 ds-oligo or mismatch-2 alternate AURKB or AURKA
ds-oligo were weak and easily dissociated (Figure 1Cb and 1Cc).
The kinetic constants calculated from fitting resulting sensor-
grams are described in Table 1. Association equilibrium con-
stants (KA) for the interaction between both PIPs and matchFigure 1. DNA-Binding Assay Results
(A) Target sequence and structure of PIP-A (Aa) and PIP-B (Ab) targeting AURKA or AURKB promoter.
(B) Electromobility shift assay (EMSA) results.
(Ba) PIP-A bindings for oligonucleotides (oligo). Lane 1, ss-oligo; lane 2, match ds-oligo; lane 3, mismatch-1 ds-oligo (equivalent to 2 base mutation oligo-DNA);
*lane 4, PIP-A with match ds-oligo; lane 5, PIP-A with mismatch-1 ds-oligo; lane 6, PIP-A with mismatch-2 ds-oligo (alternative use).
(Bb) PIP-B bindings for oligonucleotides (oligo). Lane 1, ss-oligo; lane 2, match ds-oligo; lane 3, mismatch-1 ds-oligo; *lane 4, PIP-B with match ds-oligo; lane 5,
PIP-B with mismatch-1 ds-oligo; lane 6, PIP-B with mismatch-2 ds-oligo (alternative use). The clear mobility band that indicates specific binding of PIP-A and
PIP-B for each match ds-oligo was demonstrated in *lane-4, whereas no mobility band was detected for mismatch ds-oligos (lanes 5 and 6).
(C) Biacore assay results. Typical surface plasmon resonance sensorgrams for the interactions between respective PIP and match or mismatch ds-oligo are
demonstrated.
(Ca) PIP andmatch ds-oligo interaction. (Cb) PIP andmismatch-1 (equivalent to 2 basemutation) ds-oligo interaction. (Cc) PIP andmismatch-2 (alternatively use)
ds-oligo interactions.29–841, August 25, 2008 ª2008 Elsevier Ltd All rights reserved 831
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PIP Target/Type Ka (1/Ms) Kd (1/s) KA (1/M) KD (M) c
2
PIP-A match oligo: AURKA 3.84E+05 5.11E-04 7.51E+08 1.33E-09 1.04
mismatch-1 oligo:2 base mutation AURKA 4.42E+03 3.17E-03 1.39E+06 7.17E-07 0.91
mismatch-2 oligo:AURKB (alternately use) 1.72E+03 3.59E-03 4.79E+05 2.09E-06 1.31
PIP-B match oligo: AURKA 5.47E+05 2.68E-04 2.04E+09 4.90E-10 1.36
mismatch-1 oligo:2 base mutation AURKA 5.41E+03 2.19E-03 2.47E+06 4.05E-07 1.37
mismatch-2 oligo:AURKB (alternately use) 3.40E+03 4.64E-03 7.33E+05 1.36E-06 0.93
Specificity
match/mismatch-1 match/mismatch-2
PIP-A 539 1568
PIP-B 826 2785
The kinetic constants were calculated from the surface plasmon resonance sensorgrams for the interaction between PIP compounds and biotin
labeled match or mismatch oligo-DNA that were immobilized respectively on a sensor chip SA (Biacore assays). Specificity was defined as KA (match
binding)/KA (mismatch binding).
Ka, association rate constant; Kd, dissociation rate constant; KA, association equilibrium constant; KD, dissociation equilibrium constant.ds-oligo demonstrated higher values than those for the interac-
tion between both PIPs and two types of mismatch ds-oligo.
The specificity for binding of PIP to target nucleotide sequences
was defined as KA (match binding)/KA (mismatch binding) (Table
1). These data indicated that both PIP-A and PIP-B specifically
and independently bound to the respective target nucleotide
sequence.
Distribution of FITC-Labeled PIP In Vitro
The distributions of FITC-labeled PIP-A and PIP-B in HeLa cells
after 6 and 12 hr incubation are shown in Figure 2. Both FITC-
labeled PIPs in growth medium immediately permeated into cy-832 Chemistry & Biology 15, 829–841, August 25, 2008 ª2008 Elsevtoplasm from outer membrane,and localized in all nuclei of HeLa
cells incubated for 6 hr. In HeLa cells incubated for 12 hr, the
prominent accumulation and condensation of both FITC-labeled
PIPs in nuclei was demonstrated. In addition, both FITC-labeled
PIPs were present in all nuclei by 24 and 48 hr (data not shown).
Induction of AURKA and AURKB mRNA Expression
and Knockdown Effects of PIP-A and PIP-B
During G2/M Phase
HeLa cells were synchronized at the G1/S boundary by use of
the double thymidine block (DTB) protocol, as described else-
where (Tanaka et al., 2002), followed by release. Laser-scanningFigure 2. Celluar Localization of FITC-
Labeled PIP
The distributions of FITC-labeled PIP-A and PIP-B
in HeLa cells after 6 and 12 hr of incubation are
demonstrated.
(A) Bright field.
(B) FITC.
(C) Hoechst 33342.
(D) Merge.ier Ltd All rights reserved
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than 75% of the cells were arrested in the G1 phase at ‘‘time 0’’
(Figure 4A). After release from DTB, the cells were predominantly
(more than 70%) in the G2/M phase at 10 hr (Figures 3A and 3B).
The induction of AURKA and AURKBmRNA expression during
the G2/M phase was confirmed through real-time quantitative
PCR assay by using synchronized HeLa cell populations. The
levels of both AURKA and AURKB mRNA expressions were
about three times higher in the G2/M phase than in the G1 phase
(Figures 3C and 3D), which is consistent with the results of pre-
vious investigations (Kimura et al., 2004; Tanaka et al., 2002). In
addition, the knockdown effects of PIP-A and PIP-B for AURKA
and AURKB mRNA expression during the G2/M phase were
identified by real-time quantitative PCR assay. Both PIP-A and
PIP-B (10 mMeach) demonstrated significant knockdown effects
(**p < 0.01; asterisks denote a statistically significant difference)
for mRNA expression of AURKA (knockdown-efficiency [KDE] =
55.9%) and AURKB (KDE = 64.2%) in the G2/M phase (Figures
3C and 3D). Mismatch PIP (10 mM each of alternate PIP-B or
PIP-A) did not affect respective mRNA expression.
Knockdown Effect of PIP-A and PIP-B for Promoter
Activities, mRNA Expression, and Protein Levels
of AURKA and AURKB in Random Cultured Cells
In random cultured cell populations, both luciferase activity in
HeLa cells that were transfected with AURKA and AURKB pro-
moter plasmids (Figure S2) and mRNA expression of AURKA
(Figure 3E) and AURKB (Figure 3F) peaked during 12 hr of incu-
bation, which is almost consistent with cell-cycle synchroniza-
tion analysis results. Both PIP-A and PIP-B significantly de-
creased (**p < 0.01) luciferase activity (Figure S2) and mRNA
expression of AURKA and AURKB (Figures 3E and 3F) during
12 hr of incubation in a concentration-dependent manner. In ran-
dom cultured cell populations, 10 mM of both PIP-A and PIP-B
demonstrated knockdown effects for mRNA expression of
AURKA (KDE = 53.5%) and AURKB (KDE = 51.2%) that were al-
most equivalent to those in synchronized cell populations. In ad-
dition, the 1:1 combination treatment with PIP-A and PIP-B (5 mM
each) demonstrated significant knockdown effects (**p < 0.01)
for respective mRNA expression.
The protein levels of AURKA and AURKB were confirmed by
Western blot (WB) analysis (Figure 3G). In 12 hr random cultured
HeLa cells, treatment of cells with PIP-A and PIP-B demon-
strated a prominent reduction of the respective AURKA and
AURKB protein levels in a concentration-dependent manner,
compared with that in nontreated control cells (including 1%
DMSO). The knockdown effects of both PIPs, in particular 10
mM, for protein levels were almost consistent with those for
mRNA expression. In addition, the 1:1 combination treatment
with PIP-A and PIP-B (5 mM each) also demonstrated sufficient
reduction for the respective AURKA and AURKB protein levels.
Actin-b used as a loading control demonstrated steady-state
levels in all WB analysis. As supporting reference experiments,
HeLa cells were transfected with siRNA to repress AURKA or
AURKB, respectively (siRNA-A and siRNA-B; Table S1). The
siRNA-A or siRNA-B repressed each protein level, similar to
the results of both PIPs treatment (Figure 3G).
Mismatch PIP (10 mMof alternate PIP-B or PIP-A) did not affect
promoter activity (Figure S2), mRNA expression, or protein levelsChemistry & Biology 15, 8of AURKA and AURKB (Figures 3E–3G). Moreover, in WB analy-
sis, AURKB blot (mismatch) on extracts treated with PIP-A and
AURKA blot (mismatch) on extracts treated with PIP-B revealed
steady-state levels (Figure 3G). These results indicated that both
PIP-A and PIP-B act as potent and specific inhibitors for mRNA
expression of AURKA and AURKB by independently repressing
each promoter activity.
In Vitro Cell Viability Assay and Combination Assay
Results
The effects of both PIPs against several human tumor cell lines
were examined by in vitro cell viability assay under the random
cultured cells condition. The effects of both PIPs against HeLa
cells were assessed at 48 hr (Figure 4A and Table 2). The PIP-
B treatment result demonstrated more significant loss of viability
(IC50 = 11.76 mM), compared with the PIP-A treatment result
(IC50 = 25.47 mM). Moreover, the 1:1 combination treatment
with PIP-A and PIP-B revealed a potent antiproliferative effect
for HeLa cells (IC50 = 5.89 mM), compared with treatment with ei-
ther single PIP. On the basis of the data shown in Figure 4A, the
isobologram and combination index (CI) value were calculated
by use of the previously established median-effect algorithm
(Chou and Talalay, 1984; Damaraju et al., 2007) using CalcuSyn
software (version 2.0; Biosoft). The isobologram at 1:1 combina-
tion treatment was constructed for effective dose (ED) 50, 75,
and 90, indicating 50%, 75%, and 90% growth inhibition, re-
spectively (Figure 4B). The CI value at 1:1 combination treatment
was 0.256 (<1.0) (Table 2); therefore, the potent antiproliferative
synergy was demonstrated. In addition, the combination
assays were performed at different combination ratio of 3:1 or
1:3 (PIP-A:PIP-B). As a result, PIP-B’s dominant antiproliferative
synergy (CI values = 0.655 and 0.259 for 3:1 and 1:3 combina-
tion) was indicated (Table 2).
Two reference experiments were performed. As the first refer-
ence experiment, cisplatin was examined as an existent antitu-
mor agent, and its IC50 value for HeLa cells was 33.92 mM (Table
2). These data indicate that a specific DNA-binding agent such
as PIP might have more potent antiproliferative activity for hu-
man tumor cells rather than a nonspecific DNA-binding agent
such as cisplatin. As the second reference experiment, the anti-
proliferative effects of siRNA-A and siRNA-B (Table S1) were
also examined with and without the use of lipofection. With lipo-
fection, the single treatment with siRNA-A or siRNA-B demon-
strated more-potent antiproliferative effects for HeLa cells, com-
pared with PIP-A or PIP-B (Figure 4C and Table 2). These results
reflect the high KDE of both siRNAs and are consistent with WB
analysis results (Figure 3G). Moreover, in HeLa cells that were
double transfected with siRNA-A and siRNA-B, antiproliferative
synergy (CI value = 0.525) was demonstrated, similar to the
results of combination treatment with PIP-A and PIP-B
(Figure 4C and Table 2). Without lipofection, both siRNAs dem-
onstrated no antiproliferative effect for HeLa cells properly
(Figure 4C).
The antiproliferative synergy of the 1:1 combination treatment
was examined for other several human tumor cell lines assessed
at 48 hr (Figure 4D and Table 2).Overexpression of the AURKA or
AURKB genes in these selected human tumor cell lines has al-
ready been reported by previous investigators (Bischoff et al.,
1998; Carvajal et al., 2006; Kanda et al., 2005; Kimura et al.,29–841, August 25, 2008 ª2008 Elsevier Ltd All rights reserved 833
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Tanaka et al., 2002). The 1:1 combination treatment demon-
strated various grades of anti-proliferative synergy in all of these
human tumor cell lines, with IC50 values in the 5–20 mM range
(Table 2). These results revealed that the 1:1 combination treat-
ment had a broad-spectrum antiproliferative synergy for human
tumor cells. In contrast, the human normal cell lines, such as
MRC5 and HUVECs, demonstrated potent resistance to the anti-
proliferative synergy of the 1:1 combination treatment (Figure 4D
and Table 2). These data suggest that the 1:1 combination treat-
ment may not affect human normal cells within the effective
concentration range for human tumor cells.
Effect of PIP-A and PIP-B on Cell-Cycle Progression
of Human Tumor Cells
The effects of PIP-A and PIP-B on cell-cycle progression were
examined in random cultured HeLa cells by laser-scanning cy-
tometry (iCys System; CompuCyte Corp.) (Figure 5A). In the
nontreated control cells (including 1% DMSO), the cell-cycle
progression was almost completely conserved every 12 hr
(Figure 5A, lane 1). However, the 1:1 combination treatment
with PIP-A and PIP-B caused prominent confusion between 24
and 48 hr on the DNA content histograms (Figure 5A, lane 4).
This interesting phenotype indicated the serious catastrophe of
cell-cycle progression, such as failure ofmitosis and cytokinesis.
In addition, the prominent accumulation of cells with DNA con-
tents less than 2N at sub-G1 phase and greater than 4N was ob-
served during 36 to 48 hr (Figure 5A, lane 4). This abnormal cell
accumulation indicated that the former was DNA fragmentation
in apoptotic cells and the latter was DNA aneuploidy caused
by mitotic arrest. Therefore, these results strongly suggested
that the 1:1 combination treatment synergistically induced the
serious catastrophe of cell-cycle progression mediated by mi-
totic arrest followed by tumor cell death (apoptosis). Although
the dose is below both IC50 values, the single treatment with
10 mM of PIP-A or PIP-B had only a slight influence on the
cell-cycle progression (Figure 5A, lanes 2 and 3).
Apoptosis Detection Assay Results
A consequence of the mitotic abnormality induced by the PIPs
could be activation of the apoptotic pathway, particularly in the
combination treatment of cells with PIP-A and PIP-B. To identify
this possibility, HeLa cells treated with PIPs for 48 hr were
stained by FITC-conjugated Annexin V and propidium iodide
(PI) andwere subjected to the fluorescencemicroscopic analysis
(Figure 5B) and flow cytometric (FACScan) analysis (Figure 5C).
In addition, the effects of PIPs for human normal cell line wereChemistry & Biology 15, 8similarly examined using HUVECs by FACS analysis, as a refer-
ence experiment.
Most of the nontreated control cells (including 1% DMSO)
were double negative for FITC-Annexin V and PI staining
(Figure 5B, lane 1) and remained in the lower left (LL) quadrant
of dot plots (92.96%) (Figure 5Cb), which indicates the viable
cells. In contrast, a significant increase of the FITC-Annexin V-
positive cells was demonstrated in the 1:1 combination treat-
ment with PIP-A and PIP-B assessed at 48 hr (Figure 5B, lane
4), and the cells were in the lower right (LR) quadrant of dot plots
(33.66%), which indicates the early apoptotic cells (Figure 5C).
This FACS result is completely consistent with the apoptotic
cell death in cells treated with 200 mMcisplatin as a positive con-
trol (Figure 5C). In addition, the prominent ladder DNA that
revealed the apoptotic DNA fragmentation was detected in the
1:1 combination treatment (Figure 5D, lane 4). The cells treated
with 10 mM of PIP-A were almost the same as the nontreated
control cells (Figure 5B, lane 2 and Figure 5C). In single treatment
with 10 mM of PIP-B, the slight increase of the early apoptotic
cells was demonstrated in Figure 5B, lane 3 and Figure 5C.
The reference experiment result (FACS analysis) was shown in
Figure S3. In HUVECs, there was almost no effect against all of
the treatment with PIPs for 48 hr (Figure S3).
DISCUSSION
Synthetic PIP has been reported to bind target sites within nucle-
osomes and may influence chromatin structure (Bando et al.,
2002; Best et al., 2003; Dervan, 2001; Matsuda et al., 2006;
Murty and Sugiyama, 2004; Nickols and Dervan, 2007; Nickols
et al., 2007; Trauger et al., 1996; Zhang et al., 2006). Since
PIPs can be readily designed and synthesized to target any se-
quence of biological interest, they may be useful in the investiga-
tions of gene function and perhaps in gene therapy (Bando et al.,
2002; Best et al., 2003; Dervan, 2001; Matsuda et al., 2006;
Murty and Sugiyama, 2004; Nickols and Dervan, 2007; Nickols
et al., 2007; Trauger et al., 1996; Zhang et al., 2006). Inhibition
of gene expression by PIPs that target regulatory sequences
on promoter (50-flanking) regionsmay be a biologically and phys-
iologically relevant strategy because PIPs suppress the enhanc-
ing effect of transcription factors and preserve the baseline
expression of the target gene. Therefore, the suppression or
knockdown of enhanced target gene expression by PIPs may
be more practical as novel antitumor agents since PIPs can effi-
ciently inhibit only the overexpression of target gene in tumor
cells without damaging the baseline expressions required for
normal cells. Several recent investigations of PIPs have focusedFigure 3. Knockdown Effect of PIP-A and PIP-B
(A) DNA content histogram of HeLa cells released from DTB and analyzed by laser-scanning cytometry.
(B) Percentages of cells at each phase of the cell cycle in synchronized HeLa cell populations.
(C and D) Induction of AURKA and AURKB mRNA expression and knockdown effect of PIP-A and PIP-B during G2/M phase, measured by real-time quantitative
PCR assay. The data are presented as the mean ± standard deviation (SD) of six independent experiments (n = 6). Tukey’s multiple comparison test was used for
statistical analysis.
(E and F) Knockdown effects of PIP-A and PIP-B for mRNA expression in random cultured cells. Relative AURKA and B mRNA quantities (AURKA or AURKB/
GAPDH) were measured by real-time PCR assay. The data are presented as the mean ± standard deviation (SD) of six independent experiments (n = 6). Tukey’s
multiple comparison test was used for statistical analysis.
(G) WB analysis results (AURKA, AURKB, and Actin-b). Knockdown effects of PIP-A and PIP-B for protein levels in random cultured cells were measured by WB
analysis. The intensity values of respective blotting bands were analyzed by the software Multi Gauge version 3.0 of attachment in LAS3000 (Fujifilm). AU,
arbitrary unit. Actin-b is used as a loading control. As reference experiments, the siRNAs to repress each AURKA or AURKB (siRNA-A and siRNA-B) were used.29–841, August 25, 2008 ª2008 Elsevier Ltd All rights reserved 835
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PIP for Human Aurora Kinase-A and -B GeneFigure 4. In Vitro Cell Viability Assay and Combination Assay Results
The cell viability assays were performed by the WST-8 (Nacalai Tesque, Inc.) protocol. Red line represents the IC50.
(A)Cell viability assay forHeLacells treatedwithPIPsandcisplatin.Thedataarepresentedasthemean±standarddeviation (SD)of six independentexperiments (n=6).
(B) The isobologram at 1:1 combination treatment with PIP-A and PIP-B for ED 50, 75, and 90.
(C) Cell viability assay for HeLa cells transfected siRNAs with or without use of lipofection. The data are presented as the mean ± standard deviation (SD) of six
independent experiments (n = 6).836 Chemistry & Biology 15, 829–841, August 25, 2008 ª2008 Elsevier Ltd All rights reserved
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PIP for Human Aurora Kinase-A and -B Geneon the structural characterization of transcription factor-DNA
complexes within promoter sequences (Matsuda et al., 2006;
Nickols and Dervan, 2007; Nickols et al., 2007; Yang et al., 2007).
The Aurora/Ipl1p kinase family, in particular AURKA and
AURKB, is a key regulator ofmitosis and is essential for the accu-
rate and equal segregation of genomic material from parent to
daughter cells (Carvajal et al., 2006; Jung et al., 2006; Kimura
et al., 2004; Tanaka et al., 2002). The levels of mRNA expression
and protein of AURKA and AURKB are tightly regulated during
the cell-cycle by the PRE, cell-cycle dependent element (CDE),
and CHR on their respective promoters (Carvajal et al., 2006;
Jung et al., 2006; Kimura et al., 2004; Tanaka et al., 2002). Dysre-
gulation of Aurora kineses has been linked to tumorigenesis (Car-
vajal et al., 2006; Jung et al., 2006; Kimura et al., 2004; Tanaka
et al., 2002). In this study, PIP-A and PIP-B were designed not
to cover respective consensus sequences of PRE and CHR but
to span their boundary with the intention of guaranteeing the
specificity for AURKA and AURKB promoter sequences. Both
PIPs demonstrated strong, fast, and specific binding to the
respective target DNA in the EMSA and Biacore assays. Best
et al. (2003) reported that various fluorescein-conjugated PIPs
exhibit good nuclear uptake in a wide variety of cell lines. In our
in vitro experiments, FITC-labeled PIP-A and PIP-B were distrib-
uted immediately and sufficiently in the nuclei of cultured cells
Table 2. In Vitro Tumor Cell Growth Inhibiting Activity of PIP-A
and PIP-B
Cell Type IC50 (mM) CI (ED50)
a
HeLa Human cervical adenocarcinoma
PIP-A 25.47
PIP-B 11.76
*PIP-A + PIP-B (1:1) 5.89 0.256
*PIP-A + PIP-B (3:1) 15.41 0.655
*PIP-A + PIP-B (1:3) 3.24 0.259
Cisplatin 33.92
siRNA-A (with lipofection) 68.75 (nM)
siRNA-B (with lipofection) 23.61 (nM)
*siRNA-A + siRNA-B (with lipofection) 7.89 (nM) 0.525
*PIP-A + PIP-B (1:1)
Human Tumor Cell Lines
T98G Glioblastoma 12.39
A549 Non-small cell lung cancer 7.57
A2780 Ovarian cancer 5.94
HCT116 Colon cancer 15.31
MCF7 Breast cancer 19.36
T47D Breast cancer >20.00
Human Normal Cell Lines
MRC5 Lung fibroblast cell 62.46
HUVECs Umbilical vein
endothelial cell
> 100.00
aCI values at ED50 were calculated by CalcuSyn software (version 2.0) on
the basis of the data of Figure 4A (ED50 = IC50). CI > 1.0 indicates antag-
onism, CI = 1.0 indicates additivity, a d CI < 1.0 indicates synergism.Chemistry & Biology 15, 8without any delivery systems andwere localized for long periods.
Nucleic acid medicines, such as antisense DNA, ribozymes,
siRNA, and decoys, have been developed as gene-silencing
agents. Decoys, in particular, inhibit the binding of target tran-
scription factors in a manner similar to that of PIPs. However,
since these agents are degraded easily by nucleases, they re-
quire drug-delivery systems to distribute sufficiently for the target
sequence in nuclei of living cells. Because PIPs are completely
resistant to nucleases and can be permeated to nuclei from outer
membranewithout any delivery system, such as lipofection, PIPs
may be more appropriate for gene-silencing agents.
Recently, the evidence linking Aurora overexpression andma-
lignancy has stimulated biological interest in developing Aurora
kinase inhibitors for cancer therapy (Carvajal et al., 2006; Ditch-
field et al., 2003, 2005; Harrington et al., 2004; Hauf et al., 2003;
Jung et al., 2006; Yang et al., 2007). Given their preclinical anti-
tumor activity and potential for tumor selectivity, several small
molecule inhibitors for Aurora kinase family (e.g., hesperadine
[Hauf et al., 2003], ZM447439 [Ditchfield et al., 2003, 2005],
MK0457 (previously VX-680) [Harrington et al., 2004], and
AZD1152 [Yang et al., 2007]) have been developed and are
undergoing evaluation in clinical trials. These small molecules di-
rectly affect kinase activity by occupying the ATP-binding pocket
(Carvajal et al., 2006; Ditchfield et al., 2003, 2005; Harrington
et al., 2004; Hauf et al., 2003; Jung et al., 2006; Yang et al.,
2007) and act as broad and nonspecific inhibitors for Aurora
kinases in a similar manner. ZM447439 inhibits AURKA and
AURKB activities (Ditchfield et al., 2003, 2005), hesperadine
reveals preferential inhibition for AURKB (Hauf et al., 2003),
and MK0457 acts as a pan Aurora kinase inhibitor (Harrington
et al., 2004). Therefore, each small molecule also induces a sim-
ilar phenotype in cell-based assays, characterized by the inhibi-
tion of phosphorylation for histone H3 on Ser10, cytokinesis, and
the development of aneuploidy (Carvajal et al., 2006; Ditchfield
et al., 2003, 2005; Harrington et al., 2004; Hauf et al., 2003;
Jung et al., 2006; Yang et al., 2007). Interestingly, although
ZM447439 and MK0457 inhibited both AURKA and AURKB
activity and induced failure of cytokinesis and apoptosis
in vitro, the phenotypes in treated cells with each agent were re-
garded as the result of inhibition for AURKB, not for AURKA
(Ditchfield et al., 2003, 2005; Harrington et al., 2004). Since the
antitumor activity of both ZM447439 and MK0457 was primarily
due to AURKB inhibition, the specific AURKB inhibitor, such as
AZD1152, have been developed (Yang et al., 2007).
In this study, PIP-A and PIP-B demonstrated significantly spe-
cific knockdown effects for mRNA expression and protein levels
of AURKA and AURKB. These results indicate that both PIPs
have potential use, predominantly as experimental tools in func-
tional analysis of Aurora kinases and as gene-silencing thera-
peutic agents, depending on the specificity of PIP-A and PIP-B
as the inhibitors. In addition, the combination treatment with
PIP-A and PIP-B revealed potent antiproliferative synergy for
human tumor cell lines in vitro. This biologically interesting
phenotype indicates that, as a result of direct binding to each tar-
get gene sequence, both PIPs specifically and independently
regulate AURKA and AURKB gene expression, respectively,(D) Cell viability assay for several human tumor cell lines and normal cell lines treated with combination of PIP-A and PIP-B. The data are presented as themean ±
standard deviation (SD) of six independent experiments (n = 6).29–841, August 25, 2008 ª2008 Elsevier Ltd All rights reserved 837
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PIP for Human Aurora Kinase-A and -B GeneFigure 5. The Effect of PIP-A and PIP-B against Cell Cycle
(A) Cell-cycle progression analysis results. DNAcontent histogramof HeLa cells treatedwith respective PIPs in randomcultured cell conditions, analyzed by Laser-
scanning cytometry. Lane 1, nontreated control cells (including 1%DMSO); lane 2, PIP-A (10 mM); lane 3, PIP-B (10 mM); and lane 4, 1:1 PIP-A + PIP-B (5 mMeach).838 Chemistry & Biology 15, 829–841, August 25, 2008 ª2008 Elsevier Ltd All rights reserved
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PIP for Human Aurora Kinase-A and -B Geneand cause prominent growth inhibition of tumor cells synergisti-
cally. The combination assay results indicate the PIP-B domi-
nant antiproliferative synergy and are consistent with previous
investigations using ZM447439 and MK0457 (Ditchfield et al.,
2003, 2005; Harrington et al., 2004). In addition, these results
suggest that the more practical antiproliferative synergy might
be obtained by variously changing the combination rate of PIP-
A and PIP-B. The effectiveness of combination treatment was
also confirmed by the supporting reference experiments using
siRNAs. This synergistic phenotype resulted from the catastro-
phe of cell-cycle progression due to the combination treatment
with both PIPs. This result indicates that the combination treat-
ment induces the development of aneuploidy caused by mitotic
arrest, cellar growth inhibition, and apoptosis, consistent with
the results of previous investigations (Carvajal et al., 2006; Ditch-
field et al., 2003, 2005; Harrington et al., 2004; Hauf et al., 2003;
Jung et al., 2006; Yang et al., 2007). However, each PIP specif-
ically degraded the total protein level of AURKA or AURKB due to
suppressing gene expression, without inhibition of the respec-
tive kinase activities. Therefore, the synergy of PIP-A and PIP-
B appeared more gradually, compared with the effect of previ-
ously reported small molecule kinase inhibitors (Carvajal et al.,
2006; Ditchfield et al., 2003, 2005; Harrington et al., 2004; Hauf
et al., 2003; Jung et al., 2006; Yang et al., 2007). Moreover,
IC50 values of combination treatment for various tumor cell lines
were within the 3–20 mM range. Regrettably, these effective dose
ranges were significantly higher than those of previously re-
ported small molecule kinase inhibitors and siRNAs and were in-
consistent with the binding (Biacore) assay results, with dissoci-
ation constants within nanomolar range. We speculate that one
of the major reasons for these results is the mild KDE of PIPs
for gene expression. The each KDE of 10 mM of PIP-A and
PIP-B was 50% in the real-time quantitative PCR assay and
WB analysis. These results may suggest that the recognizable
sites that both PIPs target (7 or 8 bp) are of insufficient length
to provide high specificity in the in vitro assays using cellular sys-
tems, although the high and specific binding constants of PIPs
for target sequences are confirmed in cell-free analysis systems,
such as Biacore. If the binding ability of PIPs for target sequence
is only dependent on the recognition for linear combination of
Watson-Crick base pairs, the PIP that is designed to recognize
7 or 8 bp site needs to distinguish 13,000–50,000 different
candidate sequences (Dervan, 2001). However, the candidate
binding sites of PIP must be more limited actually since PIP se-
lectively recognizes and binds to the open and intact sequences
in the minor groove of double-helical DNA (Dervan, 2001). To
solve this query, further studies based on the comprehensive
analysis to investigate the global effects of PIP using gene chip
assay (Nickols and Dervan, 2007) or the improvement of the
structure of PIP as a chemical compound (Bando et al., 2002;
Murty and Sugiyama, 2004; Zhang et al., 2006) may be needed.Chemistry & Biology 15, 8Normal human cell lines were resistant to the antiproliferative
synergy of the combination treatment with PIP-A and PIP-B.
These results suggest that the combination treatment may
have significantly selective toxicity for proliferating tumor cells
in vitro. Both PIP-A and PIP-B are designed to target the cell-
cycle-dependent positive regulatory (enhancing) regions on the
respective AURKA and AURKB promoter sequences. Therefore,
this selectivity may be based on inhibitory effects of both PIPs
only for the cell-cycle-dependent overexpression of AURKA
and AURKB in tumor cells, without damaging the baseline ex-
pression required for normal cells. However, in the present
study, the unfavorable toxicity of both PIPs to rapidly dividing
human normal cells in the hematopoietic and gastrointestinal
systems was not examined; therefore, further investigation of
the pharmacological safety of both PIPs is needed using
in vivo toxicology animal studies.
SIGNIFICANCE
In conclusion, we developed novel small molecule PIPs tar-
geting AURKA and AURKB promoters—PIP-A and PIP-B, re-
spectively. Our observations indicated that PIP-A and PIP-B
specifically inhibited both mRNA expression and protein
levels of AURKA and AURKB as a result of binding to the ac-
tive regions on the respective promoters. In addition, both
PIPs revealed potent antiproliferative synergy to human
tumor cell lines as a result of inducing apoptosis-mediated
severe catastrophe of cell-cycle progression. These results
suggest that PIP-A and PIP-B may be selectively toxic to
proliferating tumor cells and, therefore, open up new oppor-
tunities to develop novel antitumor agents. To our knowl-
edge, there has been no report such as this study, and
further investigation and development concerning PIPs
targeting AURKA and AURKB are expected.
EXPERIMENTAL PROCEDURES
This study was approved by the Nihon University Institutional Review Board.
Polyamide Synthesis: Machine-Assisted Solid-Phase Protocols
All PIP compounds were synthesized at Gentier Biosystems, Inc. (Kyoto, Ja-
pan). PIP-A and PIP-B were purchased from Gentier Biosystems, Inc. Both
PIPs were synthesized according to previously established methods (Bando
et al., 2002; Murty and Sugiyama, 2004; Zhang et al., 2006). The synthesis
protocol of PIP is briefly described as follows.
All machine-assisted PIP syntheses were performed on a Pioneer Peptide
Synthesizer (Applied Biosystems) with a computer-assisted operation system
at a 0.10 mmol scale (100 mg of wang resin, 0.96 mequiv/g) by using Fmoc
chemistry. The following conditions were used in all PIP solid-phase syntheses
for each cycle: deblocking for 5 min with 20% piperidine/DMF, activating for 2
min with 0.5 M HCTU/DMF and 1.0 M DIEA/ DMF, coupling for 60 min, and
capping for 5 min with 5% acetic anhydride/5% pyridine/DMF. After the com-
pletion of the synthesis, the resin was washedwith amixture of methanol/DCM(B) Apoptosis detection assay-1: Fluorescence microscopic analysis results. Lane 1, nontreated control cells (including 1%DMSO); lane 2, PIP-A (10 mM); lane 3,
PIP-B (10 mM); and lane 4, 1:1 PIP-A + PIP-B (5 mM each). (a) Bright field, (b) Annexin V FITC, (c) propidium iodide (PI), and (d) merge.
(C) Apoptosis detection assay-2: Flow cytometric analysis results. x axis,: Annexin V-FITC fluorescence (log scale); and y axis, PI fluorescence (log scale). Total
analysis cell counts, 40000. LL (lower left), viable cells; LR (lower right), early stage of Apoptosis; UR (upper right), progressive (late) stage of apoptosis or
necrosis. C-1, nonlabeled control (Annexin V-FITC and PI double negative); C-2, nontreated control cells (including 1% DMSO); C-3, PIP-A (10 mM); C-4,
PIP-B (10 mM); C-5, (1:1) PIP-A + PIP-B (5 mM each); and C-6, positive control treated with 200 mM cisplatin.
(D) Apoptosis detection assay result. 3, DNA fragmentation detection assay results. Lane 1, nontreated control cells (including 1% DMSO); lane 2, PIP-A
(10 mM); lane 3, PIP-B (10 mM); a d lane 4, 1:1 PIP-A + PIP-B (5 mM each).29–841, August 25, 2008 ª2008 Elsevier Ltd All rights reserved 839
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PIP for Human Aurora Kinase-A and -B Gene(1/1, v/v) (3 ml) and was dried by vacuum desiccation. The resin was then
placed in a 20 ml glass scintillation vial, 5 ml of dimethylamino propylamine
was added, and the solution was stirred at 55Covernight. Resin was removed
by filtration through a pad of Celite and was washed thoroughly with methanol/
DCM (1/1, v/v). The residue was dissolved in approximately 0.5 ml of DMF. The
resulting PIP solution was analyzed and purified by analytical HPLC as follows;
Chemcobond 5-ODS-H reversed phase column (1503 20 mm) in 0.1% AcOH
with acetonitrile as eluent at a flow rate of 9.9 ml/min appropriate gradient
elution conditions, and detection at 254 or 370 nm. After confirmation by
ESI-Mass, appropriate fractions were lyophilized to give the final desired poly-
amides as white powders.
DNA-Binding Assay
For the EMSA, FITC-labeled match 22 bp oligo corresponding to AURKA and
AURKB promoters including respective PIP-A and PIP-B binding sites were
synthesized (Table S1). In addition, the mismatch-1 22 bp oligo, including 2 bp
mutations within respective PIP-A and PIP-B binding sites, were prepared
(Table S1). The appropriate sense and antisense oligo-DNA were annealed
for preparing double strand (ds)-oligo. The binding reaction was performed
at 37C for 1 hr in 20 ml binding buffer containing 10 mM ds-oligo and 50 mM
PIP. Gel electrophoresis was performed on a 20% polyacrylamide gel at
300V for 3–4 hr at 4C. The EMSA results were visualized by luminescent im-
age analyzer LAS3000 (Fujifilm).
The kinetics for binding of PIP to the target sequence were evaluated by the
surface plasmon resonance technique with a molecular interaction model.
Biotin-labeled match oligo corresponding to AURKA and AURKB promoters
and mismatch oligo including 2 bp mutations were synthesized (Table S1).
Biotin-labeled oligos were annealed for double strand and were immobilized
(1 mM) on a streptavidin-functionalized sensor chip SA (Biacore). The kinetics
of interaction between PIP and biotin-labeled ds-oligo were measured using
Biacore 2000 system (Biacore). The data of binding responses were fitted to
Langmuir double molecular interaction model with mass transport.
Distribution of FITC-Labeled PIP In Vitro
HeLa cells were seeded on 6-well plates, to 3.03 104 cells per well, and were
grown in 2 ml of Dulbeco’s modified Eagle’s medium (DMEM) (Sigma) with
10% fetal calf serum (FCS) (Sigma) and antibiotics. Cells were maintained at
37C in 5% CO2. After 24 hr, HeLa cells were incubated with final 10 mM of
FITC-labeled PIP in growth medium for 6, 12, 24, and 48 hr, respectively. After
incubation with FITC-labeled PIP, cells were viewed at 2003magnification un-
der live cell conditions. Afterward, cells were washed with phosphate-buffered
saline (PBS) and fixed in 4% paraformaldehyde for 10min. Nuclei were stained
by Hoechst 33342 (Invitrogen) for 30 min and then were viewed again.
Construction of Promoter Plasmid for AURKA and AURKB
To obtain 50-flanking regions of AURKA and AURKB gene, human genomic
DNA was extracted from human blood cells using the conventional phenol-
chloroform method and ethanol precipitation. Using this human genomic
DNA as a template, 1.8 and 2.4 kb of the 50-flanking regions of AURKA and
AURKB gene (including the first exon) were amplified using a standard PCR
technique. Two pairs of primers that were specific for AURKA and AURKB pro-
moters were prepared (Table S1). The restriction enzyme linker was incorpo-
rated into the 50 end of each primer (Table S1). Both gel-purified PCR products
were digested at both ends by restriction enzymes and then were cloned into
the pGL3-basic firefly luciferase-reporter plasmid (Promega). The sequence of
each DNA fragment inserted into the pGL3-basic vector was confirmed by
direct sequencing in both strands.
Dual-Luciferase Reporter Assay
HeLa cells were seeded on 24-well plates and grown until preconfluence in
DMEM with 10% FCS. The pGL3-basic reporter plasmid, including AURKA
or AURKB promoter, was transiently cotransfected into HeLa calls together
with phRG-TK vector (Promega) using Lipofectamine2000 (Invitrogen) as de-
scribed previously (Jung et al., 2006; Matsuda et al., 2006; Tanaka et al., 2002).
Firefly luciferase activity values of each reporter plasmid were normalized by
Renilla luciferase activity valuesexpressed fromphRG-TKvector as the internal
control, to allow for variation in transfection efficiency. Luciferase activity was
measured using a Wallac 1420 multilabel counter (Amersham Bioscience).840 Chemistry & Biology 15, 829–841, August 25, 2008 ª2008 ElsevCell-Cycle Synchronization Analysis
HeLa cells were seeded on 6-well plates to 3.0 3 104 cells per well and were
synchronized at the G1/S boundary by a DTB protocol as previously described
(Tanaka et al., 2002). The DNA content of cells was analyzed by laser-scanning
cytometry (iCys System; CompuCyte Corp.) during the time course after
release from DTB.
Real-Time Quantitative PCR Assay
Total RNA was extracted from the collected appropriate HeLa cell lysates,
using an RNeasy-Mini Kit (QIAGEN Science), and then was reverse-tran-
scribed using a PrimeScript RT reagent Kit (TaKaRa Bio Inc.) according
to the manufacturer’s instructions. AURKA and AURKB mRNA expression
were analyzed by real-time quantitative PCR assay (Thermal Cycler Dice
Real Time System; TaKaRa Bio Inc.) using SYBR Premix Ex Taq (TaKaRa
Bio Inc.). The expression level of GAPDH gene was used as the internal con-
trol to normalize for differences in input cDNA. Assay-on-Demand primers for
AURKA (HA038310), AURKB (HA089596), and GAPDH (HA067812), which
were set from exons separated by introns, were purchased from TaKaRa
Bio Inc. (Table S1).
Western Blot Analysis
Preconfluent HeLa cells were cultured with 10% FCS medium and were un-
treated or exposed to various concentrations of PIPs for 12 hr. Lysates were
clarified by centrifugation at 1500 rpm for 3 min with PBS, the signaling of
the cells was stopped by adding SDS-sample buffer, and the extracts were
loaded to SDS-PAGE and transferred a polyvinylidene difluoride membrane
(Millipore, Bedford, MA). After transfer, the blots were incubated with blocking
solution (5% skim milk) in washing buffer (20 mM Tris-HCl [pH 7.4], 8% NaCl,
and 0.0005% Tween-20) and were probed with primary antibodies diluted in
the blocking solution, respectively. Total AURKA, AURKB, and Actin-b were
detected with anti-AURKA, AURKB, and Actin-b antibody (abcam). These
signals were identified using HRP-conjugated secondary antibodies and
enhanced chemiluminescent substrate (Millipore, Bedford, MA), according
to the manufacturer’s instructions, and were visualized by a luminescent
image analyzer LAS3000 (Fujifilm).
RNAi Technique
Stealth siRNAduplexes (Invitrogen) designed to repress AURKA and AURKB
(siRNA-A and siRNA-B; Table S1) were transfected using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions.
In Vitro Cell Viability Assay and Combination Effect Analysis
All cell lines were seeded on a 96-well microplate to 3.03 103 cells per well and
cultured in DMEMwith 10%FCS at 37C in 5%CO2. The tested PIPs were dis-
solved in growth medium at appropriate concentrations and were treated for
48 hr. In addition, cisplatin was purchased from Sigma. The nontreated control
cells were cultured inmedia containing 1%DMSO. Resultingmetabolically ac-
tive cells were evaluated by the subsequence color reaction. The cell viability
assayswere performed using theWST-8 (Nacalai Tesque, Inc.) protocol. The
absorbance (A450) of each well was measured using a Wallac 1420 multilabel
counter (Amersham Bioscience).
The CI values at ED50 were calculated by the previously establishedMedian-
effect algorithm (Chou and Talalay, 1984; Damaraju et al., 2007) using Calcu-
Syn software (version 2.0; Biosoft) based on the data of in vitro cell viability
assay (ED50 = IC50). CI > 1.0 indicates antagonism, CI = 1.0 indicates additivity,
and CI < 1.0 indicates synergism.
Cell-Cycle Progression Analysis
HeLa cells were seeded on 6-well plates to 3.0 3 104 cells per well and were
cultured with 10% FCS medium. After incubation for 6 hr, the medium was
switched to the new one containing final 10 mM of PIP. This time point
was designated ‘‘time 0.’’ After 12, 24, 36, and 48 hr of incubation, the mono-
layer cells were washed with PBS and fixed in 4% paraformaldehyde for
10 min. Nuclei were stained by Hoechst 33342 (Invitrogen) for 30 min, and
then the DNA content of cells was analyzed by laser-scanning cytometry
(iCys system). In general, more than 1.0 3 103 cells were examined in
each well. Each phase of the cell-cycle was determined on the basis of
the DNA contents.ier Ltd All rights reserved
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The apoptosis detection assay was performed using an Annexin V FITC Apo-
ptosis Detection Kit (Calbiochem), according to the manufacturer’s instruc-
tions. In brief, preconfluent (5.0 3 105–1.0 3 106) HeLa cells were cultured
with 10% FCS medium and treated with 10 mM of PIP for 48 hr. The cells
were washed with PBS, stained with FITC-conjugated Annexin V and propi-
dium iodide (PI), and then were subjected to the fluorescence microscopy
analysis or the Becton Dickinson (BD) flow cytometric (FACScan) analysis.
In FACS analysis, 4.0 3 104 cells were examined in each sample. In addition,
apoptotic DNA fragmentation was detected using a Suicide Track DNA Lad-
der Isolation Kit (Calbiochem), according to the manufacturer’s instructions.
Statistical analysis
The statistical analysis, such as ANOVA and Tukey’s multiple comparison test,
was calculated using data analysis software program SPSS 13.0 for Windows.
A value of p < 0.05 was considered statistically significant.
ACCESSION NUMBERS
The sequence for the gene encoding AURKA is available from the DDBJ/
EMBL/GenBank database under accession number AL121914. The
sequence for the gene encoding AURKB is also available from the DDBJ/
EMBL/GenBank database under accession number AC135178.
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